Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donal P McLornan

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|August 8, 2022
Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMTCarmelo Gurnari, Donal P McLornan
British Journal of Haematology|March 14, 2020
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasmsDonal P McLornan, Claire N Harrison
Hematology. American Society of Hematology. Education Program|December 10, 2017
Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyondClaire N Harrison, Donal P McLornan
Best Practice & Research. Clinical Haematology|November 4, 2022
Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approachAlexandros Rampotas, Rupen Hargreaves, Donal P McLornan
Expert Opinion on Pharmacotherapy|September 22, 2015
Pacritinib: a new agent for the management of myelofibrosis?Yan Beauverd, Donal P McLornan, Claire N Harrison
Haematologica|April 4, 2020
Bone marrow niche dysregulation in myeloproliferative neoplasmsNatalia Curto-Garcia, Claire Harrison, Donal P McLornan
Therapeutics and Clinical Risk Management|October 16, 2020
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to DateSarah Bassiony, Claire N Harrison, Donal P McLornan
Blood Reviews|June 16, 2020
Current and future therapies for myelofibrosisSamir Asher, Donal P McLornan, Claire N Harrison
Current Research in Translational Medicine|February 26, 2022
Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practiceRupen Hargreaves, Claire N Harrison, Donal P McLornan
Future Oncology (London, England)|January 24, 2020
Current and future role of fedratinib in the treatment of myelofibrosisMonica Ragheb, Claire N Harrison, Donal P McLornan
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|August 8, 2022
Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMTCarmelo Gurnari, Donal P McLornan
British Journal of Haematology|March 14, 2020
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasmsDonal P McLornan, Claire N Harrison
Hematology. American Society of Hematology. Education Program|December 10, 2017
Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyondClaire N Harrison, Donal P McLornan
Best Practice & Research. Clinical Haematology|November 4, 2022
Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approachAlexandros Rampotas, Rupen Hargreaves, Donal P McLornan
Expert Opinion on Pharmacotherapy|September 22, 2015
Pacritinib: a new agent for the management of myelofibrosis?Yan Beauverd, Donal P McLornan, Claire N Harrison
Haematologica|April 4, 2020
Bone marrow niche dysregulation in myeloproliferative neoplasmsNatalia Curto-Garcia, Claire Harrison, Donal P McLornan
Therapeutics and Clinical Risk Management|October 16, 2020
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to DateSarah Bassiony, Claire N Harrison, Donal P McLornan
Blood Reviews|June 16, 2020
Current and future therapies for myelofibrosisSamir Asher, Donal P McLornan, Claire N Harrison
Current Research in Translational Medicine|February 26, 2022
Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practiceRupen Hargreaves, Claire N Harrison, Donal P McLornan
Future Oncology (London, England)|January 24, 2020
Current and future role of fedratinib in the treatment of myelofibrosisMonica Ragheb, Claire N Harrison, Donal P McLornan
Pageof 12